Anticytokine Autoantibodies in COVID-19

在自身抗体研究中，诺塔兰格洛博士从新冠肺炎队列中获得的患者样本和对照样本被全面筛查，以确定是否存在抗细胞因子自身抗体。还进行了功能研究，以验证阳性样本是否含有中和抗体。我们发现，大约10%的重症新冠肺炎患者的I型干扰素中和抗体水平较高。一份描述这些结果的手稿目前正在一家主要期刊上进行审查。 对于新冠肺炎监测，美国国立卫生研究院临床中心启动了一项新的临床方案(20-I-0117)。这是一项对暴露于严重急性呼吸综合征冠状病毒-2(SARS-CoV-2)的个人进行的前瞻性纵向队列研究。其目的是将反转的结果关联起来 使用不同样本类型、检测和培养的转录-聚合酶链式反应(RT-PCR)。我们将对接触过报告、疑似或已知病例的NIH员工进行连续筛查。我们还将登记以前或现在感染过病毒但在登记时没有症状的个人。该系列筛查将在28天内的多个时间点进行，使用鼻咽拭子、唾液样本、中鼻甲拭子、抗体分析和培养的RT-PCR测试。该方案的注册工作最近已经开始。

For Autoantibody study, patient samples from the COVID-19 cohort obtained by Dr. Notarangelo, and control samples, were comprehensively screened for the presence of anticytokine autoantibodies. Functional studies were also performed to verify if positive samples contained neutralizing antibodies. We found that approximately 10% of patients with severe COVID-19 has high levels fo neutralizing antibodies against type I interferons. A manuscript describing these results are currently under review at a major journal. For COVID-19 surveillance, a new clinical protocol was initiated at the NIH Clinical Center (20-I-0117). This is a prospective longitudinal cohort study of individuals with exposure to severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2). The aim is to correlate results of reverse transcription-polymerase chain reaction (RT-PCR) using various sample types, assays, and culture. We will perform serial screenings of NIH employees who have had contact with reported, suspected or known cases. We will also enroll individuals with previous or current infection who are asymptomatic at enrollment. The serial screenings will be done at multiple timepoints over 28 days using RT-PCR tests of nasopharyngeal (NP) swabs, saliva samples, midturbinate swabs, antibody assays and culture. Enrollment on this protocol has recently begun.